Compare ARK Genomic Revolution ETF (ARKG) vs Marqeta Inc (MQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Marqeta Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Marqeta Inc trades at $15.8 (market cap $1.67B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | MQ | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $27.32 |
52-Week Low | $23.09 | $15.04 |
Market Cap | — | $1.67B |
Enterprise Value | — | $972.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
MQ trades at $15.87, up 2.32% today, with a bearish technical signal and neutral oscillators. Revenue has improved from $507M in 2024 to $625M in 2025, though net income remains negative. The company recently announced a 4:1 reverse stock split effective July 1, 2026, and will report Q2 2026 earnings on August 4, 2026. Analyst consensus is a buy rating with a $19.00 price target, indicating potential upside from current levels.
MQ shows revenue growth and expanding European presence, but profitability is weak with a high P/E of 396.75. Risks include ongoing net losses, competitive fintech pressures, and shareholder litigation. The stock offers speculative growth potential if execution improves, but investors face significant fundamental and sentiment headwinds near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
